Cingulate (CINGW) Non-Current Debt (2023 - 2025)
Cingulate's (CINGW) quarterly Non-Current Debt came in at $1.2 million in Q4 2025, down 52.75% on a YoY basis from $2.4 million in Q4 2024, and up 24.66% quarter-over-quarter from $923698.0 in Q1 2025.
Analysis
Cingulate (CINGW) Non-Current Debt (2023 - 2025) Analysis & Trends
Cingulate (CINGW) has reported Non-Current Debt for 3 consecutive years, with $1.2 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Debt fell 52.75% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2025 stood at $1.2 million (down 52.75% YoY), and the FY2025 full-year result was $1.2 million, down 52.75% from the prior year.
- Non-Current Debt advanced to $1.2 million in Q4 2025 per CINGW's latest filing, from $923698.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $2.4 million in Q4 2024 and bottomed at $923698.0 in Q1 2025.
- Historically, Non-Current Debt has averaged $1.7 million across 3 years, with a median of $2.1 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Non-Current Debt climbed 16.04% in 2024, then tumbled 52.75% in 2025.
- Over 3 years, Non-Current Debt stood at $2.1 million in 2023, then advanced by 16.04% to $2.4 million in 2024, then sank by 52.75% to $1.2 million in 2025.
- According to Business Quant data, Non-Current Debt over the past three periods registered $1.2 million, $923698.0, and $2.4 million for Q4 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.46 Bn | 623.70 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 440.11 Bn | 433.54 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 365.04 Bn | 357.90 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 60.50 Bn |
| 6 | Sanofi | 52.47 Bn | 45.09 Bn | 10.79 Bn | 17.02 Bn |
| 7 | Revolution Medicines | 44.26 Bn | 44.26 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | - |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.15 Mn |
| Mar 31, 2025 | 923,698.00 |
| Dec 31, 2024 | 2.44 Mn |
| Dec 31, 2023 | 2.10 Mn |
| Sep 30, 2023 | 2.10 Mn |